chemical · input

Pharmaceutical-Grade Sodium Chloride (NaCl)

Ultra-high purity NaCl (≥99.9%) meeting USP/EP monograph requirements for injection use: ultra-low endotoxin (<0.5 EU/g), heavy metals limits, and strict particle specifications. Distinct from food or industrial salt — requires dedicated pharmaceutical-grade production lines and certificate of analysis for each lot.

5

Source countries

7

Companies

1

Goods affected

0

Claims on record

What depends on it

Goods that need this input

1 essential American goods rely on pharmaceutical-grade sodium chloride (nacl) somewhere upstream in their supply chain.

Where it comes from

Source countries

Share of global supply, by country.

CountryShare of supply
USUnited States25%
DEGermany22%
CNChina20%
GBUnited Kingdom12%
INIndia8%

Who makes it

Supplier companies

7 companies produce pharmaceutical-grade sodium chloride (nacl).

K+S AG(SDF)

HQ DE18% share

German potash and salt mining company and leading supplier of pharmaceutical-grade sodium chloride (API-NaCl) globally, with approximately 18% market share in the pharma NaCl segment. Produces pharmaceutical-grade NaCl from solution mining operations with dedicated GMP-certified processing lines.

Cargill Salt (Cargill, Inc.)

HQ US15% share

American agricultural and food commodity conglomerate (private, HQ Wayzata MN; revenue ~$177B — largest private company in the US by revenue); Cargill Salt division produces pharmaceutical-grade NaCl for IV fluid manufacturers alongside its food-grade and industrial salt operations. Cargill operates rock salt mines, solar evaporation ponds, and vacuum crystallization plants across North America producing tens of millions of tonnes of salt annually. Cargill's pharma-grade NaCl uses dedicated cleanroom crystallization lines with full USP/EP compliance. The same Cargill that handles one-quarter of US grain exports and is deeply embedded in global commodity agriculture also makes the pharmaceutical salt in hospital IV bags — one of the world's most private companies (no public filings) operating at the intersection of food, energy, and medicine.

Morton Salt, Inc.

HQ US12% share

American salt company (HQ Chicago IL; K+S AG subsidiary since 2009); the most recognized salt brand in the United States — the Morton Salt Girl and 'When it rains it pours' slogan have been in use since 1914. Morton Salt produces pharmaceutical-grade NaCl (Morton Pharma brand) alongside its iconic consumer and food-grade products. Morton's pharma operations serve US IV fluid manufacturers including Baxter International and B. Braun. The company behind the most familiar American kitchen staple also manufactures the pharmaceutical salt that goes into the IV bags in every US hospital. Morton also road salt (de-icing) — the same company that keeps Chicago's streets clear in winter makes the NaCl in chemotherapy IV solutions.

Tata Chemicals Europe (Cheshire Salt Works)

HQ GB10% share

British subsidiary of Tata Chemicals Ltd. (India; Tata Group); operates the Cheshire Salt Works in Middlewich, Cheshire — one of the world's oldest salt-producing sites (the Romans extracted salt from Cheshire's brine springs around 100 AD, and continuous salt production has continued since medieval times). Tata Chemicals Europe produces pharmaceutical-grade vacuum salt meeting USP/EP monograph requirements, supplied to European IV fluid manufacturers. The Cheshire salt field (a massive natural underground brine deposit) has been a strategic resource for British chemical industry since the Industrial Revolution — it powered the Brunner Mond alkali industry (now Solvay/Ineos) that made 19th-century Britain the world's largest chemical producer.

B. Braun Medical

HQ DE

Second largest US IV fluid manufacturer, holding approximately 23% of the US market. Has invested over $1 billion across three US manufacturing sites since 2019. Operates facilities in Irvine CA, Daytona Beach FL, and Allentown PA. Produces non-PVC/non-DEHP IV bag products.

ICU Medical(ICUI)

HQ US

Third largest US IV fluid producer, formed through 2017 acquisition of Pfizer's Hospira Infusion Systems. Entered joint venture with Japan's Otsuka Pharmaceutical Factory in 2025 (renamed Otsuka ICU Medical LLC), combining Austin TX plant with Otsuka's 16 IV solution sites across Asia.

Otsuka Pharmaceutical Factory

HQ JP

Japanese pharmaceutical manufacturer operating 16 IV solutions production sites across Asia. In 2025 completed joint venture with ICU Medical (acquiring 60% stake in Otsuka ICU Medical LLC) to enter the North American IV solutions market. Combined venture produces an estimated 1.4 billion IV units annually globally.